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Edited by Angel NebredaAbstract Hepatitis C virus (HCV) is a positive-strand RNA
virus that frequently causes persistent infection associated with
severe liver disease. HCV nonstructural protein 5A (NS5A) is
essential for viral replication. Here, the kinase Raf-1 was identi-
ﬁed as a novel cellular binding partner of NS5A, binding to the
C-terminal domain of NS5A. Raf-1 colocalizes with NS5A in the
HCV replication complex. The interaction of NS5A with Raf-1
results in increased Raf-1 phosphorylation at serine 338. Integ-
rity of Raf-1 is crucial for HCV replication: inhibition of Raf-1
by the small-molecule inhibitor BAY43-9006 or downregulation
of Raf-1 by siRNA attenuates viral replication.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Hepatitis C virus (HCV) is a positive-strand RNA virus of
approximately 9600 bp. Acute infection is often mild or inap-
parent. However, the virus persists in the majority of the cases.
Persistent infection is associated with a high risk of liver cir-
rhosis and/or hepatocellular carcinoma [1].
The viral RNA codes for one large open reading frame
(ORF) of approximately 3000 amino acids that is posttransla-
tionally processed by cellular and viral proteases. The N-termi-
nus encodes the structural proteins core, E1 and E2 and the
C-terminus encodes the nonstructural proteins p7, NS2,
NS3, NS4A, NS4B, NS5A and NS5B [2].
The study of the life cycle of HCV has been hampered by the
lack of an eﬃcient cell culture system. This limitation was at
least partially overcome by the introduction of selectable rep-
licons that allow the analysis of HCV replication in cell culture
[3]. Although cells harboring the full-length replicon RNA do
not produce any infectious HCV particles, the replication com-
plex is readily formed at the endoplasmatic reticulum [4].
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doi:10.1016/j.febslet.2005.12.071in NS5A aﬀect the rate of HCV replication [5,6]. This indicates
that NS5A is not only physically present in the replication
complex but adopts a central role during HCV replication.
NS5A is capable of interacting with a number of host cell
proteins [7]. Some of these interaction partners seem to be rel-
evant in terms of triggering a deregulation of host cell signal
transduction, such as Grb2 [8], phosphatidylinositol 3-kinase
[9] or p53 [10]. Among the multitude of cellular proteins that
interact with NS5A, only the human vesicle-associated protein
hVAP-A is known to be necessary for viral replication [11].
The identiﬁcation of cellular interaction partners of NS5A
that are functionally relevant for replication is of great interest,
both with regard to understanding HCV biology and with re-
gard to the development of novel antiviral strategies.2. Materials and methods
2.1. Materials
The NS5A gene was kindly provided by Dr. Kunitada Shimotohno
(Kyoto University, Japan) and was derived from a genotype Ib isolate
(Gene Bank Accession Number D16435). StrepTactin sepharose was
obtained from IBA (Goettingen, Germany). HCV replicon cell lines
HuH-7 I377/NS3-3
0/wt/9-13 [3] and HuH-7 I389/NS3-3 0/LucUbiNeo-
ET [12] were generously donated by Dr. Ralf Bartenschlager (Univer-
sity of Heidelberg, Germany). Antibodies were obtained from the
following sources: HA (Santa Cruz), V5 (Invitrogen), Raf-1 (BD
Transduction Laboratories and Santa Cruz), phospho-Raf (Ser 338)
(Upstate), phospho-MEK (Cell Signaling Technology), active-MAPK
(Promega), ERK2 (Santa Cruz). The rabbit-derived NS5A-speciﬁc
antiserum was generated in our laboratory. BAY43-9006 and U0126
were purchased from Calbiochem. The recombinant baculovirus cod-
ing for GST-Raf-1 was provided by Dr. Walter Kolch (Beatson Insti-
tute for Cancer Research, Glasgow, UK).
2.2. Aﬃnity chromatography
A fusion protein of NS5A with an N-terminal Strep tag and a C-ter-
minal V5-epitope was isolated from a bacterial expression system and
was immobilized on a StrepTactin column (IBA, Goettingen) equili-
brated with buﬀer W (100 mM Tris/HCl, pH 8.0, 150 mM NaCl,
1 mM EDTA). The column was incubated with hepatoma cell lysate
(HuH-7) to allow potential interaction partners to bind to the immo-
bilized NS5A. After a washing step, Strep–NS5A–V5 was eluted by
buﬀer E (buﬀer W supplemented with 5 mM desthiobiotin). As con-
trols, immobilized Hepatitis-B virus core protein (HBc) (Strep–HBc)
and an unloaded StrepTactin column were used.
2.3. Immunoprecipitation, immunocomplex assay and
immunoﬂuorescence microscopy
Immunoprecipitation and immunoﬂuorescence microscopy were
performed as described [4,13]. Immunoﬂuorescence staining was ana-
lyzed by confocal laser scanning microscopy.blished by Elsevier B.V. All rights reserved.
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2.4. Quantitative immunoblotting
Naı¨ve HuH-7 cells or the HCV-replicon cell lines HuH-7 I377/NS3-
3 0/wt/9-13 and HuH-7 I389/NS3-3 0/LucUbiNeo-ET were lysed in lysis
buﬀer (100 mM Tris pH 7.5, 137 mM NaCl, 1% NP-40, 1 mM EDTA,
1 mM PMSF, 2 lg/ml leupeptin, 5 lg/ml aprotinin). Lysates were
cleared by centrifugation and subjected to SDS–PAGE and subsequent
Western blotting using rat-derived anti-phospho-Raf-1 (S338) (Up-
state) and mouse-derived anti-Raf-1 (Transduction Labs). Phospho-
Raf-1 and Raf-1 were visualized using IRDye800-conjugated anti-rat
IgG (Rockland) and Alexa-Fluor 680-conjugated anti-mouse IgG
(Molecular Probes). Immunostaining was quantiﬁed using the Odyssey
system (Li-Cor).
2.5. HCV replication assays
To monitor HCV replication, bicistronic subgenomic reporter
replicon cell lines HuH-7 I389/NS3-3
0/LucUbiNeo-ET were used as
described before [12].
2.6. Silencing of Raf-1 by RNAi
To silence Raf-1 by RNA interference, commercially available siR-
NAs (Ambion) were used. HCV replicon cells were transfected with
200 nM of siRNA using siPORT Lipid (Ambion) according to the
manufacturer’s instructions. Cells were harvested 48 h post transfec-
tion.Fig. 1. NS5A interacts with Raf-1. (A) Strep–NS5A–V5 was immo-
bilized on a StrepTactin sepharose column. Immobilized NS5A was
incubated with HuH-7 cell lysate. NS5A was eluted together with
potential binding partners. As controls, a column loaded with
Hepatitis B Virus Core (HBc) and an unloaded column were included.
Eluates were analyzed for coelution of Raf-1 by Western blotting using
a Raf-1-speciﬁc antiserum (Santa Cruz). (B, C) Strep–NS5A–V5 and
GST-Raf-1 were expressed in Sf9 cells. Sf9 cells were lysed and
subjected to immunoprecipitation as indicated. Immunoprecipitates
were analyzed by Western blotting using either a Raf-1-speciﬁc
antiserum (Santa Cruz) (B) or a V5-speciﬁc antiserum (Invitrogen)
(C).3. Results and discussion
3.1. Raf-1 binds to NS5A
To identify novel binding partners of NS5A, puriﬁed NS5A
was immobilized on an aﬃnity chromatography column. The
column was loaded with HuH-7-derived cell lysate to allow po-
tential interaction partners to bind to immobilized NS5A. Spe-
ciﬁcally binding proteins were analyzed by Western blotting.
Since NS5A has been shown to interfere with the MAP kinase
cascade and the NF-jB pathway [8,15], we focused on proteins
involved in these signaling cascades. Based on this approach,
Raf-1 was found to speciﬁcally interact with NS5A (Fig. 1A).
This was conﬁrmed by coimmunoprecipitation experiments
using cellular lysates derived from Sf9 cells that had been in-
fected with recombinant baculoviruses. The coimmunoprecip-
itation experiments show that Raf-1 is coprecipitated with
NS5A and vice versa (Fig. 1B and C).
The next set of experiments was performed to analyze
whether the interaction of Raf-1 with NS5A is reﬂected by a
colocalization in HCV replicon-containing cells. Although
these cells do not produce any infectious particles, HCV repli-
cation complexes are formed at the endoplasmatic reticulum
[4]. In these cells, NS5A displays a punctuate staining
(Fig. 2A) that arises from the clustering of the nonstructural
proteins in the replication complexes. The confocal laser scan-
ning microscopy and the intensity proﬁle show that Raf-1
colocalizes with NS5A in the replication complexes (Fig. 2A).
To analyze the interaction of Raf-1 and NS5A in more de-
tail, deletion mutants of Raf-1 and NS5A were generated.
After transient transfection of HuH-7 cells with these mutants,
their subcellular localization was determined by confocal laser
scanning microscopy. Raf-1 which lacks the catalytical domain
(Raf C4) [16] is exclusively found in the nucleus. Expression of
this mutant does not aﬀect the extranuclear localization of
NS5A (Fig. 2B) suggesting that this mutant does not bind to
NS5A.On the other hand, deletion of the N-terminal domain of
NS5A that mediates attachment to the endoplasmatic reticu-
lum was performed (NS5A 211-449). N-terminal deletion mu-
tants of NS5A are found in the nucleus [17]. Nuclear
localization of this NS5A deletion mutant resulted in a trans-
location of Raf-1 from the cytosol to the nucleus (Fig. 2C).
This indicates that the domain between amino acids 211 and
449 of NS5A is suﬃcient to mediate interaction with Raf-1.
Furthermore, this experiment shows that the interaction be-
tween Raf-1 and NS5A is strong enough to relocalize Raf-1
to a subcellular compartment that is usually devoid of Raf-1
(nucleus) [18].
3.2. Raf-1 activity is increased in HCV replicon-containing cells
The data described above show that Raf-1 interacts with
NS5A. This prompted us to analyze whether NS5A aﬀects
Raf-1 activity. Raf-1 activity is highly correlated with its phos-
phorylation status: phosphorylation at serine 338 is a critical
step in the activation of Raf-1 [19]. Therefore, we investigated
whether Raf-1 phosphorylation at serine 338 is altered in
NS5A-producing replicon cell lines (HuH-7 I389/NS3-3
0/LucU-
biNeo-ET and HuH-7 I377/NS3-3
0/wt/9-13). Fig. 3A shows
that Raf-1 phosphorylation at serine 338 is signiﬁcantly in-
creased in both HCV-replicon cell lines in comparison to naı¨ve
HuH-7 cells. To rule out that the increase in Raf-1 phosphor-
Fig. 2. Raf-1 is colocalized with NS5A in the replication complex. (A) HCV replicon cells (HuH-7 I377/NS3-3
0/wt/9-13) were stained for NS5A using
an NS5A-speciﬁc antiserum and Raf-1 using anti-Raf-1 (BD Transduction Labs). Samples were analyzed by confocal laser scanning microscopy. The
lower panel shows the intensity proﬁle corresponding to the region spanned by the white arrow in the upper panel (NS5A in green and Raf-1 in red).
(B,C) HuH-7 cells were transfected with pcDNA–HA–NS5A–V5 and pRK5-Raf C4 (B) or pcDNA–Strep–NS5A(211–449)–V5 (C). NS5A was
detected using an NS5A-speciﬁc antiserum. Endogenous Raf-1 and heterologously expressed Raf C4 were detected using anti-Raf-1 (BD
Transduction Labs).
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tion complex, HuH-7 were transiently transfected with an
NS5A expression plasmid and analyzed accordingly. Fig. 3Bshows that Raf-1 phosphorylation is increased in cells produc-
ing NS5A alone as well. To corroborate this ﬁnding, Raf-1 ki-
nase activity was analyzed in immunoprecipitates isolated
Fig. 3. Raf-1 phosphorylation is increased in HCV replicon-containing cells. (A) HCV replicon cells HuH-7 I389/NS3-3
0/LucUbiNeo-ET or HuH-7
I377/NS3-3
0/wt/9-13 and naı¨ve HuH-7 cells were analyzed by Western blotting using anti-phospho-Raf-1 (S338) (Upstate) and anti-Raf-1 (BD
Transduction Labs) in parallel. Immunostaining (anti-phospho-Raf-1 (S338)/anti-Raf-1) was quantiﬁed using the Odyssey system (Li-Cor). The bar
graph shows the summary of three independent experiments. (*) indicates a signiﬁcant increase with regard to naı¨ve HuH-7 cells (p < 0.05). (B) HuH-
7 cells were transfected with NS5A or with a control plasmid (—) and stimulated with PMA (100 ng/ml) as indicated. Immunostaining (anti-
phospho-Raf-1 (S338)/anti-Raf-1) was analyzed and quantiﬁed as described in (A). (C) Cell lysates were prepared from HuH-7 I377/NS3-3
0/wt/9-13
(lane 4) and HuH-7 cells that were transfected with a full-length HBV genome (lane 1), with a control plasmid (lanes 2 and 3) or with NS5A (lane 5)
and stimulated with 100 ng/ml PMA (lane 3). Raf-1 was precipitated from these lysates and Raf-1 activity was determined by immunocomplex assay
(using [c-32P]ATP and recombinant MEK as a substrate). Phosphorylated MEK was visualized by SDS–PAGE and autoradiography.
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con cells. Fig. 3C shows that Raf-1 kinase activity is signiﬁ-
cantly increased in NS5A-producing cells. This indicates that
binding of NS5A to Raf-1 triggers Raf-1 activation.
In contrast to this, analysis of MEK phosphorylation in
HCV replicon cell lines revealed no diﬀerence between HCV
replicon cells and naı¨ve HuH-7 cells (data not shown).
This suggests that although Raf-1 is activated in HCV repli-
con cells, the MAP kinase cascade downstream of Raf-1 is
unaﬀected.3.3. Inhibition of Raf-1 modulates HCV replication
Since Raf-1 phosphorylation was increased in the presence
of NS5A, we analyzed whether the inhibition of Raf-1 aﬀects
HCV replication in the replicon cell line HuH/LucUbiNeo-
ET [12]. To that end, Raf-1 activity was modulated by the
means of a small-molecule inhibitor (BAY43-9006) [20] or by
siRNA. Inhibition of Raf-1 by 10 lM BAY43-9006 or by
siRNA resulted in a signiﬁcantly decreased HCV replication
(Fig. 4A–D).
The next set of experiments was performed to control
whether Raf-1 exerts its eﬀect on HCV replication via the
MAP kinase signaling cascade. If this was the case, inhibition
of MEK (which acts immediately downstream of Raf-1)
should result in decreased HCV replication as well. In accor-
dance with the observation that NS5A does not trigger activa-
tion of MEK, replication was largely unaﬀected by the
presence of a small-molecule inhibitor of MEK (U0126)
(Fig. 4B). The inhibitory eﬀect of U0126 and BAY43-9006on the MAP kinase signaling cascade was conﬁrmed by Wes-
tern blotting using anti-phospho-MEK and anti-phospho-
ERK (Fig. 4A).
The eﬀect of Raf-1 inhibition on viral replication could be
explained by at least two models: (i) Raf-1 might modify some
component of the replication complex by phosphorylation.
This could either be a cellular component or a viral protein.
(ii) Alternatively, the Raf-1-mediated eﬀect on replication
could be explained as a consequence of Raf-1 signaling to-
wards downstream targets other than the MEK/ERK cascade.
Although alternative signaling pathways initiated by Raf-1 are
still poorly understood, it is emerging that Raf-1 exerts its anti-
apoptotic eﬀect by a distinct signaling pathway that culminates
in the displacement of BAD from Bcl-2 at the outer mitochon-
drial membrane [21]. Interestingly, PAK1-dependent phos-
phorylation of Raf-1 at serine 338 constitutes the major
stimulus for the mitochondrial signaling pathway of Raf-1
[22]. Therefore, NS5A might induce a conformational change
in Raf-1 that leads to the PAK1-dependent phosphorylation
of serine 338, thereby triggering a cell survival signal that is re-
quired to sustain viral replication. In contrast, inhibition of
Raf-1 may compromise its anti-apoptotic action and thereby
aﬀect HCV replication.
The data described here suggest that the inhibition of cellu-
lar signaling might be an eﬀective antiviral strategy. This is an
exciting prospect given the fact that an eﬀective cure of HCV is
still unavailable. The Raf-1 inhibitor BAY43-9006 is currently
being evaluated in clinical trials as an anti-cancer drug [23],
suggesting that it might be tolerated well enough to be applica-
ble for antiviral therapy.
Fig. 4. Inhibition of Raf-1 modulates HCV replication. (A) HCV replicon cells HuH-7 I389/NS3-3
0/LucUbiNeo-ET were preincubated with DMSO
(0.1%, 1%), U0126 (1, 10 lM) or BAY43-9006 (1, 10 lM) for 30 min and subsequently stimulated with PMA (100 ng/ml) for 20 min as indicated.
Phosphorylation of MEK and ERK was analyzed by Western blotting using anti-phospho MEK (Cell Signaling) or anti-active MAPK (Promega).
ERK2 levels were monitored using an ERK2-speciﬁc antiserum (Santa Cruz). (B) HCV replicon cells HuH-7 I389/NS3-3
0/LucUbiNeo-ET were
incubated with DMSO (1%), U0126 (1, 10 lM) or BAY43-9006 (1, 10 lM) for 6 h. Cells were harvested immediately thereafter and replication was
analyzed by measuring luciferase levels. (*) indicates a signiﬁcant reduction with regard to untreated cells (p < 0.05). (C, D) HCV replicon cells HuH-
7 I389/NS3-3
0/LucUbiNeo-ET were transfected with a Raf-1-speciﬁc siRNA or a negative control siRNA (Ambion). Cells were harvested 48 h post
transfection. HCV replication was analyzed by measuring luciferase levels (D). Raf-1 expression was monitored by Western blotting using a Raf-1-
speciﬁc antiserum (Santa Cruz) (C). As a control, expression of ERK-2 was monitored at the same time (C).
T. Bu¨rckstu¨mmer et al. / FEBS Letters 580 (2006) 575–580 579
580 T. Bu¨rckstu¨mmer et al. / FEBS Letters 580 (2006) 575–580Acknowledgments: We are grateful to Nicole Appel, Thomas Pietsch-
mann, Ralf Bartenschlager and Walter Kolch for continuing support
and helpful discussions. T.B. received a Kekule´ fellowship that was
provided by the German ‘‘Bundesministerium fu¨r Bildung und Fors-
chung’’ and the ‘‘Stiftung Stipendien-Fonds des Verbands der Chemis-
chen Industrie’’.References
[1] Hoofnagle, J.H. (2002) Course and outcome of hepatitis C.
Hepatology 36, S21–S29.
[2] Hijikata, M. et al. (1993) Proteolytic processing and membrane
association of putative nonstructural proteins of hepatitis C virus.
Proc. Natl. Acad. Sci. USA 90, 10773–10777.
[3] Lohmann, V., Korner, F., Koch, J., Herian, U., Theilmann, L.
and Bartenschlager, R. (1999) Replication of subgenomic hepa-
titis C virus RNAs in a hepatoma cell line. Science 285, 110–113.
[4] Gosert, R., Egger, D., Lohmann, V., Bartenschlager, R., Blum,
H.E., Bienz, K. and Moradpour, D. (2003) Identiﬁcation of the
hepatitis C virus RNA replication complex in Huh-7 cells
harboring subgenomic replicons. J. Virol. 77, 5487–5492.
[5] Blight, K.J., Kolykhalov, A.A. and Rice, C.M. (2000) Eﬃcient
initiation of HCV RNA replication in cell culture. Science 290,
1972–1974.
[6] Penin, F. et al. (2004) Structure and function of the membrane
anchor domain of hepatitis C virus nonstructural protein 5A. J.
Biol. Chem.
[7] Tellinghuisen, T.L. and Rice, C.M. (2002) Interaction between
hepatitis C virus proteins and host cell factors. Curr. Opin.
Microbiol. 5, 419–427.
[8] Tan, S.L., Nakao, H., He, Y., Vijaysri, S., Neddermann, P.,
Jacobs, B.L., Mayer, B.J. and Katze, M.G. (1999) NS5A, a
nonstructural protein of hepatitis C virus, binds growth factor
receptor-bound protein 2 adaptor protein in a Src homology 3
domain/ligand-dependent manner and perturbs mitogenic signal-
ing. Proc. Natl. Acad. Sci. USA 96, 5533–5538.
[9] He, Y., Nakao, H., Tan, S.L., Polyak, S.J., Neddermann, P.,
Vijaysri, S., Jacobs, B.L. and Katze, M.G. (2002) Subversion of
cell signaling pathways by hepatitis C virus nonstructural 5A
protein via interaction with Grb2 and P85 phosphatidylinositol 3-
kinase. J. Virol. 76, 9207–9217.
[10] Majumder, M., Ghosh, A.K., Steele, R., Ray, R. and Ray, R.B.
(2001) Hepatitis C virus NS5A physically associates with p53 and
regulates p21/waf1 gene expression in a p53-dependent manner. J.
Virol. 75, 1401–1407.[11] Gao, L., Aizaki, H., He, J.W. and Lai, M.M. (2004) Interactions
between viral nonstructural proteins and host protein hVAP-33
mediate the formation of hepatitis C virus RNA replication
complex on lipid raft. J. Virol. 78, 3480–3488.
[12] Frese, M., Barth, K., Kaul, A., Lohmann, V., Schwarzle, V. and
Bartenschlager, R. (2003) Hepatitis C virus RNA replication is
resistant to tumour necrosis factor-alpha. J. Gen. Virol. 84, 1253–
1259.
[13] Hildt, E. and Oess, S. (1999) Identiﬁcation of Grb2 as a novel
binding partner of tumor necrosis factor (TNF) receptor I. J. Exp.
Med. 189, 1707–1714.
[14] Hildt, E., Munz, B., Saher, G., Reifenberg, K. and Hofschneider,
P.H. (2002) The PreS2 activator MHBs(t) of hepatitis B virus
activates c-raf-1/Erk2 signaling in transgenic mice. Embo J. 21,
525–535.
[15] Macdonald, A., Crowder, K., Street, A., McCormick, C., Saksela,
K. and Harris, M. (2003) The hepatitis C virus nonstructural
NS5A protein inhibits activating protein-1 function by perturbing
ras-ERK pathway signaling. J. Biol. Chem. 278, 17775–17784.
[16] Bruder, J.T., Heidecker, G. and Rapp, U.R. (1992) Serum-, TPA-,
and Ras-induced expression from Ap-1/Ets-driven promoters
requires Raf-1 kinase. Genes Dev. 6, 545–556.
[17] Brass, V., Bieck, E., Montserret, R., Wolk, B., Hellings, J.A.,
Blum, H.E., Penin, F. and Moradpour, D. (2002) An amino-
terminal amphipathic alpha-helix mediates membrane association
of the hepatitis C virus nonstructural protein 5A. J. Biol. Chem.
277, 8130–8139.
[18] O’Neill, E. and Kolch, W. (2004) Conferring speciﬁcity on the
ubiquitous Raf/MEK signalling pathway. Br. J. Cancer 90, 283–
288.
[19] Zang, M., Waelde, C.A., Xiang, X., Rana, A., Wen, R. and Luo,
Z. (2001) Microtubule integrity regulates Pak leading to Ras-
independent activation of Raf-1 insights into mechanisms of Raf-
1 activation. J. Biol. Chem. 276, 25157–25165.
[20] Wan, P.T. et al. (2004) Mechanism of activation of the RAF-
ERK signaling pathway by oncogenic mutations of B-RAF. Cell
116, 855–867.
[21] Troppmair, J. and Rapp, U.R. (2003) Raf and the road to cell
survival: a tale of bad spells, ring bearers and detours. Biochem.
Pharmacol. 66, 1341–1345.
[22] Jin, S., Zhuo, Y., Guo, W. and Field, J. (2005) PAK1-dependent
phosphorylation of RAF-1 regulates its mitochondrial localiza-
tion, phosphorylation of BAD, and BCL-2 association. J. Biol.
Chem.
[23] Hilger, R.A. et al. (2002) ERK1/2 phosphorylation: a biomarker
analysis within a phase I study with the new Raf kinase inhibitor
BAY43-9006. Int. J. Clin. Pharmacol. Ther. 40, 567–568.
